Should We Consider Heart Rate Reduction in Cardiac Transplant Recipients?

Should We Consider another Booster Dose of Measles Vaccine?

Background: To date, 36 years has passed since the beginning of measles vaccination; the disease is still circulating around the world, threatening lives of human beings especially in developing countries.  In recent years, we have confronted measles in previously vaccinated adults from all over the country. Objective: To find out if there is a need for changing our routine measles vaccination ...

Erythema nodosum :what should we consider about it?

Cardiac allograft vasculopathy in pediatric heart transplant recipients.

Metabolic parameters for coronary allograft vasculopathy (CAV) have not been well defined in children. CAV (by angiography or autopsy) was studied in 337 heart recipients on a cyclosporine-based steroid-sparing regimen. Freedom from CAV for all was 79% at 10 years. Fifty-nine patients (18%) developed CAV at a mean of 6.5 +/- 3 years post-transplant. First year rejections were significantly high...

Power spectrum analysis of heart rate variability in human cardiac transplant recipients.

Beat-to-beat heart rate variability was studied by power spectral analysis in 17 orthotopic cardiac transplant patients. Heart rate power spectra were calculated from eighty-four 256-second recordings and compared with those taken from six normal subjects. The power spectra from the control subjects resolved into discrete peaks at 0.04-0.12 Hz and 0.2-0.3 Hz, whereas those of heart transplant r...

Cardiac allograft vasculopathy in Dutch heart transplant recipients

BACKGROUND Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of graft failure after heart transplantation. However, the impact of CAV may vary according to the definition and the regional differences in transplantation settings. OBJECTIVES We sought to assess CAV prevalence, predictors and prognosis in Dutch heart transplant recipients based on coronary angiog...